Optimisation study of α-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes

Applied Radiation and Isotopes

Volumn 63, Issue 5-6 SPEC. ISS., 2005, Pages 621-631

  Groppi, F ^a   Bonardi, M L ^a   Birattari, C ^a   Menapace, E ^b   Abbas, K ^c   Holzwarth, U ^c   Alfarano, A ^a,c   Morzenti, S ^a   Zona, C ^a   Alfassi, Z B ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b ENEA   (Italy)

^c JOINT RESEARCH CENTRE   (Italy)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

High LET metabolic radiotherapy; NCA 211At 211gPo, 210At 210Po, 209Bi( , xn) reactions

Indexed keywords

CYCLOTRONS; FISSION REACTIONS; GAMMA RAYS; IMPURITIES; IRRADIATION; ISOTOPES; PARTICLE BEAMS; RADIOTHERAPY;

HIGH-LET METABOLIC RADIOTHERAPY; IMMUNORADIOTHERAPY; NCA 211 AT 211G PO, 210 AT 210 PO 209 BI (Α, XN) REACTIONS;

RADIOISOTOPES;

ASTATINE 211; BISMUTH; POLONIUM 211; RADIOISOTOPE; UNCLASSIFIED DRUG;

ALPHA RADIATION; CONFERENCE PAPER; CYCLOTRON; EXCITATION; IRRADIATION; LINEAR ENERGY TRANSFER; MATHEMATICAL COMPUTING; METABOLISM; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY;

ASTATINE; CYCLOTRONS; POLONIUM; RADIOTHERAPY; SPECTROMETRY, GAMMA;

EID: 26444435787     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2005.05.041     Document Type: Conference Paper

References (45)

1. Abbas, K., Alfarano, A., Alfassi, Z., Apostolidis, C., Birattari, C., Bonardi, M., Gibson, N., Groppi, F., Holtzwarth, U., Menapace, E., Morgenstern, A., Morzenti, S., Stamm, H., 2004. Developmets in Alpha Emitting Radioisotopes Production at the Joint Research Centre (JRC) of the European Commission. 17th International Conference on Cyclotron and their Applications, October 2004, Tokyo, Japan, in press.
2. C. Apostolidis, R. Carlos Marquez, W. Janssen, R. Molinet, T. Nikula, and A. Ouadi Cancer treatment using Bi-213 and Ac-225 in radioimmunotherapy Nucl. News Am. Nucl. Soc. 12 2001 29 33
3. Appelman, E.H., 1960. The Radiochemistry of Astatine, US Atomic Energy Commission, Report NAS-NS 3012, Washington, DC, USA.
4. C. Birattari, M. Bonardi, F. Groppi, A. Martinotti, S. Morzenti, S. Ridone, M. Acchini, K. Abbas, A. Alfarano, U. Holzwarth, and E. Menapace First experiment for alpha-cyclotron production, radiochemical processing and quality controls of the alpha emitter astatine-211/polonium-211 g for high-LET metabolic radiotherapy Quart. J. Nucl. Med. Mol. Imag. 48 suppl.1-3 2004 in press
5. R.M.D. Carretta Current trends in Nuclear Medicine Nucl. News Am. Nucl. Soc. 12 2001 26 28
6. G. Choppin, J.O. Liljenzin, and J. Rydberg Radiochemistry and Nuclear Chemistry, Second ed. of Nuclear and Radiochemistry, Theory and Applications 2002 Butterworth-Heinemann Oxford, UK
7. H.H. Coenen, S.M. Moerelin, and G. Stöcklin No carrier added radiohalogenation methods with heavy halogens Radiochim. Acta 34 1983 47 68
8. Figgins, P.E., 1961. The Radiochemistry of Polonium, US Atomic Energy Commission, Report NAS-NS 3037, Washington, DC, USA.
9. R.B. Firestone, C.M. Baglin, and F.S.Y. Chu Table of Isotopes Eighth ed. 1998 Wiley New York, USA Update on CD-ROM
10. Herman, M., 2002. EMPIRE-II statistical model code for nuclear reaction calculations, distributed by the IAEA Nuclear Data Section, IAEA1169/06 (Liason Persons for LASA-INFN and ENEA, F. Groppi and E. Menapace).
11. J.L. Humm, and L.M. Chin A model of cell inactivation by alpha-particle internal emitters Radiat. Res. 134 1993 143 150
12. G.L. Johnson, R.F. Leininger, and E. Segrè Chemical Properties of Astatine Int. J. Chem. Phys. 17 1949 1 10
13. A.I. Kassis The amazing world of Auger electrons Int. J. Radiat. Biol. 80 2004 789 803
14. B. Kanyár, and G.J. Köteles Dosimetry and biological effects of ionizing radiation A. Vértes S. Nagy Z. Klencsár Handbook on Nuclear Chemistry Vol. 4 2003 Kluwer Academic The Netherland 349 387 Chapter 10
15. E.L. Kelly, and E. Segrè Some excitation functions of bismuth Phys. Rev. 75 7 1949 999 1005
16. 211At for cancer therapy. Sixth International Conference on Nuclear and Radiochemistry, Aachen, Germany, August 2004.
17. R.M. Lambrecht, and S. Mirzadeh Cyclotron Isotopes and Radiopharmaceuticals-XXXV. Astatine-211 Int. J. Appl. Radiat. Isot. 36 6 1985 443 450
18. K.H. Lieser Nuclear and Radiochemistry: Fundamentals and Applications 2001 Wiley and Verlag, VHC Berlin, Germany
19. 211At labeling of a monoclonal antibody and its Fab fragment: cytotoxicity on human gastric cancer cells and biodistribution in nude mice with tumor xenografts J. Radioanal. Nucl. Chem. 247 2001 129 133
20. Menapace, E., Birattari, C., Bonardi, M.L., Groppi, F., Morzenti, S., Zona, C., 2004. Comparison between theoretical calculation and experimental results of excitation functions for production of relevant biomedical radionuclides. Proceedings of the International Conference Nuclear Data for Science and Technology 2004, Santa Fe, NM, USA, September 2004, in press
21. 211Rn nuclear reaction Int. J. Appl. Radiat. Isot. 31 1980 351 355
22. R.D. Neirinckx, and J.A. Smith Separation of astatine-211 from bismuth metal Analyt. Chim. Acta 63 1973 201 204
23. 209Bi up to 70 MeV Nuovo Cim. 112 2 1999 1439 1451
24. W.J. Ramler, J. Wing, D.J. Henderson, and J.R. Huizenga Excitation function of bismuth and lead Phys. Rev. 114 1 1959 154 162
25. 209Bi at 55.7 and 58.6 MeV Radiochim. Acta 57 1992 7 9
26. 209Bi up to 60 MeV Appl. Radiat. Isot. 41 2 1990 215 219
27. Rössler, K. (Ed.), 1989. Special issue of Radiochimica Acta on Astatine Chemistry, 47, pp. 83-168.
28. N.L. Singh, S. Mukherjee, and D.R. Somayajulu Non-equilibrium analysis of (α,xn) reactions on heavy nuclei Nuovo Cim. 107 9 1994 1635 1645
29. J.A. Smith, J.A. Myburg, and R.D. Neirinckx Specific inactivation of sensitised lymphocytes in-vitro using antigens labelled with astatine-211 Clin. Exp. Immunol. 14 1973 107 116
30. 12C-induced nuclear reactions in heavy-mass targets at medium excitation energies. Experimental cross sections Phys. Rev. C 9 1974 1064 1071
31. G. Stöcklin, S.M. Qaim, and F. Rösch The impact of radioactivity on medicine Radiochim. Acta 70/71 1995 249 272
32. M.S. Sultana, A. Toyoshima, N. Takahashi, and H. Baba Distribution behavior of astatine: solvent extraction and back extraction J. Radioanal. Nucl. Chem. 247 2001 193 195
33. Z. Szuecs, F. Szelecsenyi, J. Bergman, S.J. Heselius, and O. Solin He-3 induced nuclear reactions on 209-Bi at particle energies less than 28 MeV. Production of 209-At Radiochim. Acta, 65 1994 87 91
34. T. Unak Some microdosmetric data on Astatine-211 Appl. Radiat. Isot. 58 2003 115 117
35. G. Vaidyanathan, and M.R. Zalutszy Targeted therapy using alpha emitters Phys. Med. Biol. 41 1996 1915 1931
36. G. Vaidyanathan, A. Boskovitz, S. Shankar, and M.R. Zalutszy Radioiodine and At-211-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers Peptides 25 12 2004 2087 2097
37. G.W.M. Visser, and E.L. Diemer Inorganic astatine chemistry: formation of complexes of astatine Radiochim. Acta 33 1983 145 151
38. 209Bi target for radiopharmaceutical applications J. Radioanal. Nucl. Chem. 262 3 2004 593 599
39. 211At U. Amaldi B. Larsson Y. Lemoigne In Advances in Radiotherapy 1997 Elsevier The Netherland 359 382
40. M.R. Zalutsky, and G. Vaidyanathan Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy Curr. Pharma. Des. 6 2000 1433 1455
41. M.R. Zalutsky Radionuclide therapy A. Vértes S. Nagy Z. Klencsár Handbook on Nuclear Chemistry Vol. 4 2003 Kluwer Academic The Netherland 315 342
42. M.R. Zalutsky Targeted radiotherapy of brain tumours Br. J. Cancer 90 8 2004 1469 1473
43. M.R. Zalutsky Current status of therapy of solid tumors: brain tumor therapy J. Nucl. Med. 46 2005 151S 156S
44. J.F. Ziegler, J.P. Bierzack, and U. Littmark USA The Stopping and Range of Ions in Solids Vol. I and Vol. II-VI 1985 Pergamon Press New York (new edition in 2003)
45. J.F. Ziegler SRIM 2003 code, IBM-Research 2003 Yorktown New York, USA